• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Javid J. Moslehi, MD

Instructor, Department of Medicine, Harvard Medical School

Co-Director, Cardio-Oncology Program, Cardio-Oncology Program, Dana-Farber Cancer Institute

Contact Info

Javid Moslehi
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA, 02215
Phone: 857-307-1964
Fax: 857-307-1955
javidmoslehi@gmail.com

Assistant

Tricie Gatcomb
Brigham And Women's Hospital
Phone: 857-307-1964

DF/HCC Program Affiliation

Translational Pharmacology and Early Therapeutic Trials
Cancer Survivorship

DF/HCC Associations

Scientific Advisor, Clinical Research Unit

Lab Website

http://www.cardio-onc.org

Research Abstract

Cardio-Oncology (the cardiovascular care of cancer patients) has developed as a new clinical field given the expanding repertoire of cancer therapies, which have changed the natural course of many cancers but which can lead to cardiovascular complications. Since many of these novel treatments are “targeted therapies” such that they interfere with specific pathways involved in tumor progression, cardiovascular and cardio-metabolic changes following cancer drug treatment can provide insights into human cardiovascular biology. This idea has the potential to be explored further in the many human oncology clinical trials by a closer collaboration between cardiologists and oncologists where cardiovascular and cardio-metabolic changes after modulation of specific pathways can be studied carefully in patients. In this regard, cardio-oncology may represent a new opportunity for basic and translational investigation and can serve as a potential avenue for cardiovascular drug discovery.


Our program in cardio-oncolgy is focused on providing care for cancer patients who develop cardiac complications during cancer treatment, especially in patients who receive novel molecular targeted therapies that may have cardiovascular complications, including hypertension, hyperlipidemia, acute arterial and venous thromboembolic events, acute coronary syndrome, and cardiomyopathy. The observations from patients who develop cardiac complications from novel chemotherapies will provide testable hypotheses in the laboratory, which may provide better understanding of the mechanisms of cardiac disease and may, in time, translate into improvements in patient care.

Publications

View All Publications